The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma

Creative Commons License

UYSAL A., ERKURT M. A., KUKU İ., KAYA E., BERBER İ., SARICI A., ...More

MARMARA MEDICAL JOURNAL, vol.36, 2023 (ESCI)

  • Publication Type: Article / Article
  • Volume: 36
  • Publication Date: 2023
  • Doi Number: 10.5472/marumj.1244684
  • Journal Name: MARMARA MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, TR DİZİN (ULAKBİM)
  • Inonu University Affiliated: Yes

Abstract

Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ µL in the peripheral blood (PB) on the 4th day of mobilization. Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined. Results: The median CD34+ cell count in PB on the 4th day was 5.2/µL (0.1-13.4), which was determined to increase 206.6-fold (31.57 49347) to 924.80 /µL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106). Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.